Amgen Oncology Highlights Upcoming Data Presentations at the American Society of Clinical Oncology Annual Meeting; Clinical Data to be Presented on Four Investigational Targeted Cancer Therapies

May 31, 2006

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 31, 2006--Amgen (NASDAQ:AMGN), the world's largest biotechnology company, today announced upcoming data presentations at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Atlanta. Clinical results will be presented on four investigational cancer therapies: panitumumab in metastatic colorectal cancer patients, denosumab in breast cancer patients with bone metastases, AMG 706 in advanced thyroid cancer patients, and recombinant human Apo2L/TRAIL (co-developed with Genentech, Inc.) in patients with advanced cancer. In addition, updated data evaluating every-three-week administration of darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes (MDS), and in combination with iron for the treatment of chemotherapy-induced anemia, will be presented.

"At Amgen, we take a comprehensive approach to helping patients in their fight against cancer. From our strong foundation in supportive care to our entry into innovative therapeutics, Amgen researchers are constantly evaluating new pathways and modalities for developing novel treatments," said Willard Dere, M.D., chief medical officer and senior vice president of Global Development. "We are very excited to present new data on multiple agents from our robust pipeline of investigational targeted therapies."

The following are selected studies of interest being presented on Amgen's investigational compounds and marketed products this year at ASCO:

Panitumumab

-- Panitumumab antitumor activity in patients with metastatic colorectal cancer expressing low (less than 1-9 percent) or negative (less than 1 percent) levels of epidermal growth factor receptor

   Abstract #3547 (Saturday, June 3, 8:00 a.m. - 12:00 p.m., Bldg B, Level 1, Hall B5)

-- Panitumumab antitumor activity in patients with metastatic colorectal cancer expressing greater than 10 percent epidermal growth factor receptor

   Abstract #3548 (Saturday, June 3, 8:00 a.m. - 12:00 p.m., Bldg B, Level 1, Hall B5)

Denosumab

-- Randomized, active-controlled study of denosumab (AMG 162) in breast cancer patients with bone metastases not previously treated with intravenous (IV) bisphosphonates (BP)

   Abstract #512 (Sunday, June 4, 9:15 a.m. - 9:30 a.m., Bldg C, Level 1, Hall C1, Oral Presentation)

-- A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (Pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption

   Abstract #8562 (Saturday, June 3, 2:00 p.m. - 6:00 p.m., Bldg B, Level 1, Hall B5)

AMG 706

-- Safety and antitumor activity of AMG 706 in patients with thyroid cancer: A subset analysis from a Phase 1 dose-finding study

   Abstract #3030 (Saturday, June 3, 8:00 a.m. - 12:00 p.m., Bldg C, Level 3, Room C306)

Recombinant Human Apo2L/TRAIL

-- A Phase 1 safety and pharmacokinetic study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer

Abstract #3013 (Saturday, June 3, 3:00 p.m. - 3:15 p.m., Bldg B, Level 3, Room B305)

Darbepoetin alfa

-- A randomized open-label study of darbepoetin alfa administered every 3 weeks with or without parenteral iron in anemic subjects with nonmyeloid malignancies receiving chemotherapy

Abstract #8612 (Saturday, June 3, 2:00 p.m. - 6:00 p.m., Bldg B, Level 1, Hall B5)

-- Darbepoetin alfa for treating anemia in low-risk myelodysplastic syndrome patients: Interim results after 27/28 weeks

Abstract #6564 (Saturday, June 3, 8:00 a.m. - 12:00 p.m., Bldg B, Level 1, Hall B5)

-- Darbepoetin alfa for treating anemia in patients with low-risk myelodysplastic syndromes: Exploratory analysis of baseline predictors of response

Abstract #6579 (Saturday, June 3, 8:00 a.m. - 12:00 p.m., Bldg B, Level 1, Hall B5)

Aranesp(R) (darbepoetin alfa) has not been approved by the Food and Drug Administration (FDA) for the treatment of anemia associated with myelodysplastic syndromes. Aranesp is contraindicated in patients with uncontrolled hypertension. Erythropoietic therapies may increase the risk of thrombotic events and other serious events.

Webcast Information

Amgen will host a webcast with the investment community on Sunday, June 4th, at 6:00 p.m. EDT to discuss data presented at ASCO. Open to members of the news media, investors and the general public, the webcast can be found on Amgen's Web site, www.amgen.com, under Investors. It will be archived and available for replay at least 72 hours after the event.

About Amgen

Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a broad and deep pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

Forward-Looking Statement

This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in Amgen's Form 10-K for the year ended December 31, 2005, and in Amgen's periodic reports on Form 10-Q and Form 8-K. Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify side effects or manufacturing problems with Amgen's products after they are on the market. In addition, sales of Amgen's products are affected by the availability of reimbursement and the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers, and may be affected by domestic and international trends toward managed care and healthcare cost containment as well as possible U.S. legislation affecting pharmaceutical pricing and reimbursement. Government regulations and reimbursement policies may affect the development, usage and pricing of Amgen's products. In addition, Amgen competes with other companies with respect to some of Amgen's marketed products as well as for the discovery and development of new products. Amgen believes that some of the newer products, product candidates or new

indications for existing products, may face competition when and as they are approved and marketed. Amgen products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while Amgen routinely obtains patents for Amgen's products and technology, the protection offered by Amgen's patents and patent applications may be challenged, invalidated or circumvented by Amgen's competitors and there can be no guarantee of Amgen's ability to obtain or maintain patent protection for Amgen's products or product candidates. Amgen cannot guarantee that it will be able to produce commercially successful products or maintain the commercial success of Amgen's existing products. Amgen's stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of Amgen's products or product candidates. Further, the discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on Amgen's business and results of operations.

The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. Only the FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Further, the scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the FDA for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. Only the FDA can determine whether the products are safe and effective for these uses. Healthcare professionals should refer to and rely upon the FDA-approved labeling for the products, and not the information discussed in this news release.

EDITOR'S NOTE: An electronic version of this news release may be accessed via our Web site at www.amgen.com. Journalists and media representatives may sign up to receive all news releases electronically at time of announcement by filling out a short form in the Media section of the Web site.

CONTACT: Amgen
Trish Hawkins, 805-447-4587 (media)
Arvind Sood, 805-447-1060 (investors)
SOURCE: Amgen